𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone–releasing hormone analogues AN-152 and AN-207

✍ Scribed by Jörg B. Engel; Gunhild Keller; Andrew V. Schally; Attila Nagy; David D. Chism; Gabor Halmos

Book ID
118445097
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
218 KB
Volume
83
Category
Article
ISSN
1556-5653

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Complete regression of MX-1 human breast
Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone–releasing hormone, AN-207
✍ Zsuzsanna Kahán; Attila Nagy; Andrew V. Schally; Gábor Halmos; José M. Arencibia 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

BACKGROUND. Receptors for luteinizing hormone-releasing hormone (LH-RH) are found in about 50% of human breast carcinomas. A highly potent cytotoxic agent, 2-pyrrolinodoxorubicin (AN-201), was linked to the agonist [D-Lys 6 ]LH-RH to form a cytotoxic LH-RH analog, AN-207, that can be targeted to LH-

Targeted cytotoxic analog of luteinizing
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice
✍ Kopp�n, Miklos; Nagy, Attila; Schally, Andrew V.; Plonowski, Artur; Halmos, G�bo 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB 👁 2 views

## Background: Receptors for luteinizing hormone-releasing hormone (lh-rh) found in prostate cancers might be used for targeting of chemotherapeutic agents. doxorubicin derivative 2-pyrrolinodoxorubicin (an-201) can be linked to carrier analog [d-lys6]lh-rh to form the targeted cytotoxic analog of